Arlington Partners’s BeOne Medicines Ltd ONC Stock Holding History

Arlington Partners’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13	Closed	-$4K	–	678
2021 Q4	$4K	Buy	+13	New	+$4.39K	﹤0.01%	596

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Arlington Partners's ONC Position: Q1 2022 in Review

Arlington Partners sold out of BeOne Medicines Ltd (ONC) in Q1 2022, closing a stake of 13 shares — an estimated $4K sold.

Arlington Partners first reported a position in ONC in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 238 funds tracked by Wall St. Rank hold ONC as of Q1 2022.

Arlington Partners reported no remaining BeOne Medicines Ltd position as of Q1 2022 after selling out during the quarter.
Arlington Partners sold 13 BeOne Medicines Ltd shares in Q1 2022, an estimated $4K.
Arlington Partners first reported a position in BeOne Medicines Ltd in Q4 2021 and held it in 1 quarter.
Arlington Partners's BeOne Medicines Ltd position peaked at $4K in Q4 2021.
238 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2022.

Based on Arlington Partners's 13F filing for Q1 2022, filed 14 Apr 2022.